Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria

Fagiolo, U; Kricek, Franz; Ruf, Christine; Peserico, Andrea; Amadori, Alberto; Cancian, Mauro

doi:10.1067/mai.2000.108913

Cited by 79 publications

(63 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…histamine release assays vs. immunoblotting. Nonetheless, our findings support the concept that positive cutaneous responses to autologous serum characterize a subgroup of patients suffering from ‘autoreactive’ rather than ‘autoimmune’ CU as most ASST+ skin reactions were found to occur in CU patients that did not express Fc ε RI/IgE-targeting autoantibodies [26]. …”

Section: Discussionsupporting

confidence: 65%

Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial

Staubach¹,

Onnen²,

Vonend³

et al. 2006

Dermatology

131

134

View full text Add to dashboard Cite

Background: Patients with chronic urticaria (CU) frequently exhibit positive skin test reactions to autologous serum (ASST). Therapies aimed at inducing tolerance to circulating histamine-releasing factors in ASST+ CU patients, e.g. by treatment with autologous whole blood (AWB), have not yet been tested. Objective: To test whether ASST+ CU patients can benefit from repeated low-dose intramuscular injections of AWB. Methods: We characterized CU severity and duration, anti-Fc_ΕRI and anti-IgE expression, use of antihistamines, and quality of life in 56 CU patients (ASST+: 35, ASST–: 21) and assessed the therapeutic effects of 8 weekly AWB injections in a randomized, placebo-controlled, single-blind, parallel-group trial. Results: Numbers, size, intensity, and/or duration of CU symptoms, quality of life, as well as expression of anti-Fc_ΕRI or anti-IgE were similar in ASST+ and ASST– CU patients. However, CU in ASST+ patients was of longer duration and required markedly more antihistaminic medication. Interestingly, ASST+ patients, but not ASST– patients, showed significantly (1) reduced CU activity, (2) decreased use of antihistamines, and (3) improved quality of life after AWB treatment. Placebo treatment was ineffective in both groups, but differences of AWB and placebo treatment responses did not achieve statistical significance in either group, most likely due to the limited number of patients treated. Conclusion: Our findings suggest that ASST+ CU is clinically different from other CU subforms and that ASST+ CU patients can benefit from AWB therapy.

show abstract

Section: Discussionsupporting

confidence: 65%

Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial

Staubach¹,

Onnen²,

Vonend³

et al. 2006

Dermatology

131

134

View full text Add to dashboard Cite

show abstract

“…However, recent work has shown that activation of mast cells or basophils by anti-FcεR1 autoantibodies probably involves complement activation and that the correlation between functional (histamine-releasing) and non-functional (immunoreactive) anti-FcεR1 autoantibodies is poor [52, 53]. Immunoreactive (non-functional) anti-FcεR1 autoantibodies can be found in sera of patients with autoimmune connective tissue diseases, autoimmune bullous diseases and in physical urticarias, but not in healthy individuals.…”

Section: Chronic Idiopathic Urticariamentioning

confidence: 99%

Pathophysiology of Chronic Urticaria

Greaves¹

2002

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Chronic urticaria includes several different subsets with distinct pathophysiologies, and with important implications for investigation and treatment. Chronic ‘idiopathic’ urticaria represents a special challenge, which, until recently, was not taken up by dermatological or immunological investigators. However, it has now emerged that at least 30% of patients possess histamine-releasing autoantibodies against FcΕR1, or less commonly IgE itself. These autoantibodies are causative. Recent work implicates complement activation in most cases. Functional (i.e. histamine releasing) autoantibodies are specific to chronic urticaria. However, immunoreactive (non-histamine-releasing) anti-FcΕR1 autoantibodies can be found in sera of patients with physical urticarias and with autoimmune connective tissue and bullous diseases. The reason for the occurrence of this disease type in some individuals but not others is unclear. One possibility is the development, in genetically predisposed persons, of autoantibodies by molecular mimicry – perhaps against lipopolysaccharide of Helicobacter pylori, an organism frequently infecting the upper gastrointestinal tract of chronic urticaria patients.

show abstract

“…For selected experiments, human serum was pretreated as follows. For depletion of gamma globulin, serum aliquots were treated with an equal volume of protein G-coated Sepharose beads (GE Healthcare) as previously described (6). For total inhibition of the complement system, serum was heat inactivated for 30 min at 56°C as described previously (16,28).…”

Section: Antibodiesmentioning

confidence: 99%

Neutrophils Interact with Adenovirus Vectors via Fc Receptors and Complement Receptor 1

Cotter¹,

Zaiss

Muruve³

2005

J Virol

View full text Add to dashboard Cite

Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria

Cited by 79 publications

References 16 publications

Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial

Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial

Pathophysiology of Chronic Urticaria

Neutrophils Interact with Adenovirus Vectors via Fc Receptors and Complement Receptor 1

Contact Info

Product

Resources

About